• 12479 Citations
  • 39 h-Index
1973 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
Article

A biszfo szfo nát-keze lés során és zlelhet o vese funkci ó-válto zás vizsg álata emlorákos betege inknél

Translated title of the contribution: Changes in renal function during bisphosphonate treatment of breast cancer patientsHorváth, Z., Farkas, P., Ganofszky, E., Hitre, E., Juhos, É., Nagy, T., Rubovszky, G., Szabó, E. & Láng, I., Dec 1 2008, In : Magyar onkologia. 52, 1, p. 49-55 7 p.

Research output: Contribution to journalArticle

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Price, K. N., Coates, A. S., Goldhirsch, A. & Gelber, R. D., Jul 1 2016, In : Journal of Clinical Oncology. 34, 19, p. 2221-2230 10 p.

Research output: Contribution to journalArticle

64 Citations (Scopus)

A Case-Control Study of Gallbladder Cancer in Hungary

Nakadaira, H., Lang, I., Szentirmay, Z., Hitre, E., Kaster, M. & Yamamoto, M., 2009, In : Asian Pacific Journal of Cancer Prevention. 10, 5, p. 833-836 4 p.

Research output: Contribution to journalArticle

11 Citations (Scopus)

A colorectalis carcinoma irinotecan kezelésének legújabb eredményei

Translated title of the contribution: Novel data on the irinotecan treatment of colorectal cancerIstván, L. & Erika, H., Dec 1 2004, In : Magyar onkologia. 48, 4, p. 281-288 8 p.

Research output: Contribution to journalArticle

A comparative analysis on the efficacy and safety of intaxelspi® and taxolspi® in advanced metastatic breast cancer

Lang, I., Rubovszky, G., Horvath, Z., Ganofszky, E., Szabo, E., Dank, M., Boer, K. & Hitre, E., Jun 1 2013, In : Journal of Clinical and Diagnostic Research. 7, 6, p. 1120-1124 5 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Action of cyclic nucleotides in antibody dependent cellular cytotoxicity reactions

Lang, I., Kalmar, L. & Gergely, P., Jan 1 1978, In : Kiserletes Orvostudomany. 30, 3, p. 300-305 6 p.

Research output: Contribution to journalArticle

Activity tests on concanavalin A-induced suppressor cells in autologous and allogenous systems

Gergely, P., Gonzalez Cabello, R., Lang, I. & Kalmar, L., Jan 1 1980, In : Kiserletes Orvostudomany. 32, 5, p. 514-518 5 p.

Research output: Contribution to journalArticle

Adjuvant Anti-HER2 Therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients

Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, Gelber, R. D. & De Azambuja, E., Jan 1 2019, In : Journal of the National Cancer Institute. 111, 1, djy094.

Research output: Contribution to journalArticle

15 Citations (Scopus)

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial

Francis, P., Crown, J., Di Leo, A., Buyse, M., Balil, A., Andersson, M., Nordenskjöld, B., Lang, I., Jakesz, R., Vorobiof, D., Gutiérrez, J., Van Hazel, G., Dolci, S., Jamin, S., Bendahmane, B., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M. & Piccart-Gebhart, M., Jan 2008, In : Journal of the National Cancer Institute. 100, 2, p. 121-133 13 p.

Research output: Contribution to journalArticle

125 Citations (Scopus)

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., Ciruelos, E., Stearns, V., Bonnefoi, H. R., Martino, S., Geyer, C. E., Pinotti, G., Puglisi, F., Crivellari, D., Ruhstaller, T., Winer, E. P. & 13 others, Rabaglio-Poretti, M., Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Bernhard, J., Luo, W., Ribi, K., Viale, G., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Francis, P. A., Jan 1 2014, In : New England Journal of Medicine. 371, 2, p. 107-118 12 p.

Research output: Contribution to journalArticle

306 Citations (Scopus)

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, M., Holmes, E., Baselga, J., De Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., McCullough, A. E., Dolci, S., McFadden, E., Holmes, A. P., Tonghua, L., Eidtmann, H., Dinh, P., Di Cosimo, S., Harbeck, N., Tjulandin, S. & 15 others, Im, Y. H., Huang, C. S., Díeras, V., Hillman, D. W., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R. D. & Perez, E. A., Apr 1 2016, In : Journal of Clinical Oncology. 34, 10, p. 1034-1042 9 p.

Research output: Contribution to journalArticle

170 Citations (Scopus)

Adjuvant ovarian suppression in premenopausal breast cancer

Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., Martino, S., Davidson, N. E., Geyer, C. E., Walley, B. A., Coleman, R., Kerbrat, P., Buchholz, S., Ingle, J. N., Winer, E. P. M., Rabaglio-Poretti, M. & 9 others, Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Colleoni, M., Viale, G., Coates, A. S., Goldhirsch, A. & Gelber, R. D., Jan 1 2015, In : New England Journal of Medicine. 372, 5, p. 436-446 11 p.

Research output: Contribution to journalArticle

312 Citations (Scopus)

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a " standard chemotherapy regimen": The CASA randomized trial

Crivellari, D., Gray, K. P., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K. N., Láng, I., Gianni, L., Spazzapan, S., Pinotti, G., Lüthi, J. M., Gelber, R. D., Regan, M. M., Colleoni, M., Castiglione-Gertsch, M., Maibach, R., Rabaglio, M., Coates, A. S. & Goldhirsch, A., Apr 2013, In : Breast. 22, 2, p. 130-137 8 p.

Research output: Contribution to journalArticle

28 Citations (Scopus)

Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M. & Baselga, J., Jul 13 2017, In : New England Journal of Medicine. 377, 2, p. 122-131 10 p.

Research output: Contribution to journalArticle

333 Citations (Scopus)

Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC).

Boér, K., Láng, I., Juhos, E., Pintér, T. & Szántó, J., 2003, In : Pathology oncology research : POR. 9, 3, p. 166-169 4 p.

Research output: Contribution to journalArticle

11 Citations (Scopus)

A hanging manover újabb indikációi a májsebészetben.

Translated title of the contribution: [Latest indications for hanging manoeuvre in liver surgery].Jakab, F., Dede, K., Láng, I., Bursics, A. & Mersich, T., Dec 2012, In : Magyar sebészet. 65, 6, p. 407-415 9 p.

Research output: Contribution to journalArticle

A humán antitest-dependens celluláris cytotoxicitás (ADCC) vizsgálata allogén rendszerben.

Translated title of the contribution: Study of human antibody-dependent cellular cytotoxicity (ADCC) in an allogenic systemLáng, I., Fekete, B., Gergely, P. & Petrányi, G., Jul 24 1977, In : Orvosi hetilap. 118, 30, p. 1763-1765 3 p.

Research output: Contribution to journalArticle

A metiléntetrahidrofolát-reduktáz (MTHFR) C677T polimorfizmus klinikai jelentősége a metasztatikus colorectalis daganatok 5-fluoropirimidin-alapú kezelésében

Barna, B., Erika, H., Vilmos, A., Ferenc, C., Fruzsina, G., István, L. & Judit, K., Jan 1 2004, In : Magyar onkologia. 48, 3, p. 253-257 5 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

A modern emlo{double acute}sebészet onkoplasztikai kihívásai

Translated title of the contribution: Oncoplastic challenges in modern breast surgeryMátrai, Z., Gulyás, G., Tóth, L., Polgár, C., Bidlek, M., Szabó, É., Láng, I., Horváth, Z., Udvarhelyi, N., Kunos, C., Sávolt, Á., Pesthy, P. & Kásler, M., 2011, In : Magyar onkologia. 55, 1, p. 40-52 13 p.

Research output: Contribution to journalArticle

8 Citations (Scopus)

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study

Colleoni, M., Giobbie-Hurder, A., Regan, M. M., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Láng, I., Smith, I., Chirgwin, J., Pienkowski, T., Wardley, A., Price, K. N., Gelber, R. D., Coates, A. S. & Goldhirsch, A., Mar 20 2011, In : Journal of Clinical Oncology. 29, 9, p. 1117-1124 8 p.

Research output: Contribution to journalArticle

100 Citations (Scopus)

Antibody-dependent and spontaneous cell-mediated cytotoxicity in children with acute lymphoblastic leukemia

Lang, I., Zoltan, E., Revesz, T., Gergely, P., Schuler, D. & Petranyi, G., Dec 1 1982, In : Allergologia et immunopathologia. 10, 5, p. 341-345 5 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Antibody dependent and spontaneous lymphocyte mediated cytotoxicity in normal subjects, patients with SLE, and malignancies

Lang, I., Benczur, M., Varga, M., Gergely, P. & Petrányi, G., Dec 1 1977, In : Acta medica Academiae Scientiarum Hungaricae. 34, 3, p. 123-127 5 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Antibody-dependent cellular cytocoxicity in systemic lupus erythematosus

Lang, I., Fekete, B., Paloczi, K., Sonkoly, I., Szegedi, G., Török, K., Gergely, P. & Petrányi, G., Dec 1 1977, In : Acta medica Academiae Scientiarum Hungaricae. 34, 4, p. 259-265 7 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Antibody-dependent cellular cytotoxic activity in patients with Hodgkin disease

Lang, I., Berenyi, E., Szegedi, G., Török, K., Fekete, B. & Gergely, P., Dec 1 1977, In : Acta medica Academiae Scientiarum Hungaricae. 34, 4, p. 241-245 5 p.

Research output: Contribution to journalArticle

Antibody dependent cellular cytotoxicity of lymphocytes in patients with renal diseases of immunopathological origin

Lang, I., Kenez, B., Nagy, Z. K., Sonkoly, I., Pálóczi, K., Szegedi, G., Fekete, B. & Gergely, P., Dec 1 1978, In : Clinical Nephrology. 9, 3, p. 111-114 4 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

A pet/ct szerepe az emlörák diagnosztikájában és kezelésében - összefoglaló az eddig megszerzett ismeretekrõl és a kutatás további irányairól

Translated title of the contribution: Role of PET/CT in diagnosis and treatment of breast cancer - Review on present knowledge and current research trendsBalázs, M., Zsolt, H., István, L., Miklós, K. & Katalin, B., 2012, In : Magyar onkologia. 56, 1, p. 23-29 7 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Bennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T. Y., Pover, G. M., Morris, C. D. & Douillard, J. Y., Oct 1 2011, In : Investigational New Drugs. 29, 5, p. 1021-1028 8 p.

Research output: Contribution to journalArticle

93 Citations (Scopus)

A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer

Dittrich, C., Solska, E., Manikhas, A., Eniu, A., Tjulandin, S., Anghel, R., Musib, L., Frimodt-Moller, B., Liu, Y., Krejcy, K. & Láng, I., May 1 2012, In : Cancer Investigation. 30, 4, p. 309-316 8 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

Martin, M., Bonneterre, J., Geyer, C. E., Ito, Y., Ro, J., Lang, I., Kim, S. B., Germa, C., Vermette, J., Wang, K., Wang, K. & Awada, A., Dec 1 2013, In : European Journal of Cancer. 49, 18, p. 3763-3772 10 p.

Research output: Contribution to journalArticle

83 Citations (Scopus)

A simple allogeneic test system for the study of antibody-dependent cellular cytotoxicity (ADCC) in man.

Láng, I., Fekete, B., Gergely, P. & Petrányi, G., Dec 1 1977, In : Haematologia. 11, 1-2, p. 85-91 7 p.

Research output: Contribution to journalArticle

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K. N., Gelber, R. D., Coates, A. S. & Thürlimann, B., Nov 1 2011, In : The Lancet Oncology. 12, 12, p. 1101-1108 8 p.

Research output: Contribution to journalArticle

261 Citations (Scopus)

A tripla-negatív emlokarcinóma - Irodalmi áttekintés

Translated title of the contribution: Triple negative breast carcinoma - Rewiev of current literatureRubovszky, G., Udvarhelyi, N., Horváth, Z., Láng, I. & Kásler, M., Dec 1 2010, In : Magyar onkologia. 54, 4, p. 325-335 11 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Az emloárák belgyógyászati onkológiai (gyógyszeres) kezelése

Láng, I., Kahán, Z., Pintér, T., Dank, M., Boér, K., Pajkos, G., Faluhelyi, Z., Pikó, B., Eckhardt, S. & Horváth, Z., Sep 1 2010, In : Magyar onkologia. 54, 3, p. 237-254 18 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Az emlorák korszeru gyógyszeres kezelése

Translated title of the contribution: Modern pharmacological therapy of breast cancerLáng, I., Kahán, Z., Hitre, E., Dank, M., Rubovszky, G., Horváth, Z. & Kásler, M., Jan 1 2012, In : Orvosi hetilap. 153, 2, p. 56-65 10 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Az emlorák korszeru képalkotó diagnosztikája: nukleárismedicina-technikák

Translated title of the contribution: Modern diagnostics of breast cancer: Nuclear medicine techniquesKatalin, B., István, S., Balázs, M., Zsolt, H., István, L. & Miklós, K., Jan 1 2012, In : Orvosi hetilap. 153, 1, p. 14-21 8 p.

Research output: Contribution to journalArticle

Az emlótumor csontveló mikrometasztázisának klinikai jelentósége.

Translated title of the contribution: Clinical significance of bone marrow micrometastases of breast tumorsDubecz, S., Csuka, O., Török, K., Vasas, N., Péley, G., Doleschal, Z., Sulyok, Z., Láng, I. & Köves, I., Aug 2003, In : Magyar sebészet. 56, 3-4, p. 108-112 5 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Az epeúti carcinomák gyógyszeres kezelé sének lehetõségei. Múlt - Jelen - Jóvo

Translated title of the contribution: Opportunities in drug therapy of biliary tract cancer. Past - Present - FutureGábor, R., Erika, H. & István, L., Jul 24 2013, In : Lege Artis Medicinae. 23, 5-6, p. 255-261 7 p.

Research output: Contribution to journalArticle

Az epidermális növekedési faktor recept orát célzó terápiák RAS paradoxona vastag- és végbélrákban

Translated title of the contribution: The RAS paradoxon of the EGFR-targeted therapy of colorectal cancerTímár, J. & Láng, I., Dec 1 2008, In : Magyar onkologia. 52, 2, p. 185-191 7 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Az indometacin lymphocyta proliferációt fokozó hatása in vivo.

Translated title of the contribution: Lymphocyte proliferation-enhancing effect of indomethacin in vivoKalmár, L., Rhenzo, G. C., Láng, I., Gergely, P. & Fehér, J., Nov 24 1985, In : Orvosi hetilap. 126, 47, p. 2889-2893 5 p.

Research output: Contribution to journalArticle

Az MR-vizsgálat szerepe a rectumcarcinomák terápiájának meghatározásában

Translated title of the contribution: Role of MRI in determining the therapy of rectal cancerJederán, É., Mátrai, Z., Tóth, L., Lövey, J., Láng, I., Hitre, E., Naszádos, G. & Godény, M., 2012, In : Magyar onkologia. 56, 3, p. 179-186 8 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial

Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D. & Saunders, M. P., Oct 1 2013, In : The Lancet Oncology. 14, 11, p. 1077-1085 9 p.

Research output: Contribution to journalArticle

324 Citations (Scopus)

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., Villanueva, C., Romieu, G., Lang, I., Ciruelos, E., De Laurentiis, M., Veyret, C., de Ducla, S., Freudensprung, U., Srock, S. & Gligorov, J., Oct 1 2014, In : The Lancet Oncology. 15, 11, p. 1269-1278 10 p.

Research output: Contribution to journalArticle

93 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, Open-label, Non-inferiority, Phase 3 TURANDOT trial

Lang, I., Brodowicz, T., Ryvo, L., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Messinger, D. & Zielinski, C., Feb 1 2013, In : The Lancet Oncology. 14, 2, p. 125-133 9 p.

Research output: Contribution to journalArticle

75 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D. & Brodowicz, T., Sep 1 2016, In : The Lancet Oncology. 17, 9, p. 1230-1239 10 p.

Research output: Contribution to journalArticle

24 Citations (Scopus)

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., Colleoni, M., Pienkowski, T., Nogaret, J. M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A. & Coates, A. S., Jan 1 2009, In : Annals of Oncology. 20, 9, p. 1489-1498 10 p.

Research output: Contribution to journalArticle

106 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor exemestane: A phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 346-347 2 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausalwomen evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 348-349 2 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study

Rubovszky, G., Láng, I., Ganofszky, E., Horváth, Z., Juhos, É., Nagy, T., Szabó, E., Szentirmay, Z., Budai, B. & Hitre, E., Dec 1 2013, In : European Journal of Cancer. 49, 18, p. 3806-3812 7 p.

Research output: Contribution to journalArticle

34 Citations (Scopus)
32 Citations (Scopus)

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Van Cutsem, E., Köhne, C. H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., Schlichting, M., Zubel, A., Celik, I., Rougier, P. & Ciardiello, F., May 20 2011, In : Journal of Clinical Oncology. 29, 15, p. 2011-2019 9 p.

Research output: Contribution to journalArticle

1247 Citations (Scopus)